ATE510552T1 - Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors - Google Patents

Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors

Info

Publication number
ATE510552T1
ATE510552T1 AT97929783T AT97929783T ATE510552T1 AT E510552 T1 ATE510552 T1 AT E510552T1 AT 97929783 T AT97929783 T AT 97929783T AT 97929783 T AT97929783 T AT 97929783T AT E510552 T1 ATE510552 T1 AT E510552T1
Authority
AT
Austria
Prior art keywords
thyrotropine
receptor
human
producing secreted
short variants
Prior art date
Application number
AT97929783T
Other languages
English (en)
Inventor
Basil Rapoport
Sandra Mclachlan
Original Assignee
Basil Rapoport
Sandra Mclachlan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basil Rapoport, Sandra Mclachlan filed Critical Basil Rapoport
Application granted granted Critical
Publication of ATE510552T1 publication Critical patent/ATE510552T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97929783T 1996-06-05 1997-06-05 Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors ATE510552T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1917196P 1996-06-05 1996-06-05
PCT/US1997/009624 WO1997046206A2 (en) 1996-06-05 1997-06-05 Human thyrotropin receptor compositions and use thereof

Publications (1)

Publication Number Publication Date
ATE510552T1 true ATE510552T1 (de) 2011-06-15

Family

ID=21791804

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97929783T ATE510552T1 (de) 1996-06-05 1997-06-05 Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors

Country Status (6)

Country Link
EP (1) EP0959896B1 (de)
JP (1) JP2000512280A (de)
AT (1) ATE510552T1 (de)
AU (1) AU3376297A (de)
CA (1) CA2258720A1 (de)
WO (1) WO1997046206A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395096T3 (es) * 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AU2002231353A1 (en) * 2000-10-26 2002-05-06 Deltagen, Inc. Knockout mice thyroid stimulating hormone receptor (tsh-r) gene
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (de) 2008-06-20 2021-12-29 MannKind Corporation Interaktives Gerät für die Echtzeit-Profilierung von Inhalationsversuchen
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
ES2747634T3 (es) * 2013-05-14 2020-03-11 Siemens Healthcare Diagnostics Inc Formulaciones líquidas estabilizadas que contienen receptores
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008726A1 (en) * 1990-11-15 1992-05-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Rat thyrotropin receptor gene and uses thereof

Also Published As

Publication number Publication date
EP0959896A4 (de) 2005-03-02
WO1997046206A2 (en) 1997-12-11
JP2000512280A (ja) 2000-09-19
CA2258720A1 (en) 1997-12-11
EP0959896B1 (de) 2011-05-25
AU3376297A (en) 1998-01-05
EP0959896A2 (de) 1999-12-01

Similar Documents

Publication Publication Date Title
EP0959896A4 (de) Zusammensetzungen auf der grundlage des humanen thyrotropinrezeptors und ihre verwendung
NO951138D0 (no) Mikropartikkelpreparater fremstilt fra biologisk nedbrytbare blandingspolymerer
ATE234124T1 (de) Verfahren zur herstellung von wirkstoffhaltigen knochenzementen
DE69506668D1 (de) Vorrichtung zur herstellung von weichen tissueprodukten
DE69327659D1 (de) Therapeutische und diagnostische bilderzeugungzusammensetzung und verfahren zur herstellung
ATE231724T1 (de) Kombinationstherapie für die behandlung von psychosen
ATE185971T1 (de) Kombinationspräparat zur behandlung hypogonadaler männer sowie männern mit hypophysenerkrankungen
IL128003A0 (en) Therapeutic multispecific compounds comprised of anti-fcalpha receptor antibodies
HUT76970A (hu) Készítmény az érrendszer specifikus koagulálásához
PL332432A1 (en) Oxadiazoles, method of obtaining them as well as their application as therapeutic agents
ATE271393T1 (de) Zusammensetzungen zur erhöhung des hautdurchtritts von arzneistoffen unter verwendung von permeationsbeschleunigern
DE69730224D1 (de) Verfahren und instrument zur untersuchung des herzens und der arterien
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
DE69707607D1 (de) Enzymbehandeltes Hesperidin, Verfahren zur Herstellung und Verfahren zur Verwendung von enzymbehandeltem Hesperidin
EP0866893A4 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
DE69622051D1 (de) Verfahren zur herstellung von 2,4-dihydroxy-pyridin und 2,4-dihydroxy-3-nitropyridin
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE69737067D1 (de) Vakzine zur behandlung von mycosen
DK0786004T3 (da) Kloning, ekspression og karakterisering af en hidtil ukendt form af phosphatidylinositol-3-kinase
ATA232687A (de) Zahnpflegemittel, sowie verfahren zur herstellung des zahnpflegemittels
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties